Surpass topical anti-inflammatory cream offers a more efficient way to manage pain with the first and only FDA-approved formulation of diclofenac diclofenac sodium 1% for veterinary use. It is indicated for the control of pain and inflammation associated with osteoarthritis OA in tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal hock, knee, fetlock and pastern joints in horses. Because it's applied only where needed in very small amounts, it reduces the risk of toxicity associated with the use of systemic NSAIDsAdd this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
Dosage and Administration:
Follow your Veterinarian's prescription instructions for your pet.
Apply a five-inch 5 ribbon of Surpass topical cream twice daily over the affected joint for up to ten days.
Wear rubber gloves to prevent absorption into the hands. Rub the cream thoroughly into the hair covering the joint until it disappears.
Surpass topical cream is contraindicated in animals with known hypersensitivity to diclofenac.
Not for horses intended for human consumption.
Keep out of reach of children.
Not for human use.
Consult a physician in case of accidental ingestion by humans.
Wear gloves to prevent absorption into the hands.
Direct contact with the skin should be avoided.
If contact occurs, the skin should be washed immediately with soap and water. Animal
For topical use in horses only.
Owners should be advised to observe for signs of potential drug toxicity See Information for Owner or Person Treating Animal and Adverse Reactions.
Exceeding the recommended dosage or treating multiple joints may increase plasma concentrations of diclofenac.The systemic effects of excess diclofenac doses that exceed the recommended label amount and duration have not been evaluated. Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Owners should be advised to observe for signs of potential drug toxicity See Information for Owner or Person Treating Animal. Treatment with Surpass Cream should be terminated if signs such as inappetence, colic, fecal abnormalities, anemia or depression are observed. As a class, NSAIDs may be associated with gastrointestinal and renal toxicity. When NSAIDs inhibit prostaglandins that cause inflammation, they may also inhibit prostaglandins that maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease more often than in healthy patients. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular and/or hepatic dysfunction. Studies to determine the effect of Surpass topical cream when administered concomitantly with other drugs have not been conducted. Since many NSAIDs possess the potential to induce gastric ulceration, concomitant use of Surpass Cream with any other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided. Drug compatibility should be monitored closely in patients receiving adjunctive therapy. The safety of Surpass Cream has not been investigated in breeding, pregnant or lactating horses, or in horses under one year of age.
During the field study, one diclofenac-treated horse developed colic on day four of the study and responded to symptomatic treatment. One placebo-treated horse exhibited mildly jaundiced mucous membranes on day five. Adverse reactions during the safety study included a gastric ulcer in one horse that received 5.6X the recommended dosage, diarrhea and uterine discharge in one horse that received 2.8X the recommended dosage, and weight loss in four of the six horses in the 5.6X dosage group.